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Abstract
The effects of cell cycle inhibition on the expression of the multidrug resistance transporter P-glycoprotein (P-gp) as well as
of the cyclin-dependent kinase (CDK) inhibitors p27Kip1 and p21WAFÿ1 were investigated in DU-145 prostate tumor
spheroids. With increasing spheroid size the number of cells in the G0/G1 phase augmented, whereas the number of cells in
the G2/M phase and the S phase of the cell cycle declined. The number of G0/G1 cells was elevated after incubation with
either mimosine, staurosporine or serum-free medium. Mitomycin C and roscovitine increased the number of S phase cells.
Roscovitine additionally increased cells in the G2/M phase. Incubation in serum-free medium upregulated p21WAFÿ1, p27Kip1
and P-gp. Mimosine treatment resulted in upregulation of p27Kip1 and P-gp, whereas p21WAFÿ1 remained unchanged. Upon
roscovitine treatment p27Kip1 and p21WAFÿ1 were downregulated, whereas P-gp was unaltered. Mitomycin C treatment
resulted in downregulation of p27Kip1 and p21WAFÿ1 ; no significant change in P-gp levels was observed. Staurosporine
induced upregulation of p21WAFÿ1 whereas p27Kip1 remained unaltered. P-gp was downregulated upon staurosporine
treatment, which was owing to an elevation of intracellular reactive oxygen species by this compound. It is concluded that
upregulation of P-gp in G0/G1 phase cells requires coexpression of the CDK inhibitor p27Kip1 but not the CDK inhibitor
p21WAFÿ1. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Although it is well documented that solid tumors
in vivo show a proliferative heterogeneity that is cor-
related to resistance towards chemotherapeutic drugs
and radiation, there is yet not su⁄cient experimental
evidence that tumor cell dormancy is involved in the
induction of P-glycoprotein (P-gp) expression. Pre-
vious studies suggest that the high percentage of dor-
mant cells in the depth of the tumor tissue may be
the main regulator for the development of multidrug
resistance (MDR) [1]. In this respect serum starva-
tion, which causes growth arrest in many cell lines,
has been demonstrated to induce the expression of
the mdr-1 gene in human and mouse tumor cell lines,
which was regulated at the transcriptional level in a
promoter sequence-speci¢c manner [2]. Conse-
quently, stimulation of cell proliferation induced
downregulation of P-gp levels in tumor cells as re-
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cently evidenced in multicellular prostate tumor
spheroids [3] as well as in leukemic blasts [4]. How-
ever, it remains unclear so far whether speci¢c cell
cycle phases in tumor lesions are correlated with in-
creased expression of P-gp.
Quiescent, proliferation-inactive cell areas occur
physiologically in the depth of multicellular tumor
spheroids which are a well established in vitro model
system for avascular micrometastases and avascular
regions of large tumors [5]. In large multicellular
tumor spheroids a high expression level of the cy-
clin-dependent kinase (CDK) inhibitor p27Kip1 was
observed and discussed to play a role as a resistance
factor [6]. Overexpression of p27Kip1 resulted in in-
crease of MDR in transfected cell lines [7]. In con-
trast, the use of antisense oligonucleotides down-
regulating p27Kip1 resulted in the loss of spheroid
aggregation and signi¢cant cellular sensitization to
alkylating agents [6]. In multicellular prostate tumor
spheroids an elevated intrinsic resistance towards the
anticancer agent doxorubicin was recently observed
with increasing diameter of multicellular spheroids
[8] and P-gp identi¢ed as the regulator of resistance
[9]. Interestingly, P-gp was found to be expressed
predominantly in deeper, quiescent cell layers, indi-
cating that the cell cycle arrest may induce P-gp ex-
pression. Additional factors that have been discussed
to induce drug resistance in large tumor spheroids
may be low pH, hypoxia and central necrosis which
are well known to occur in the depth of avascular
tumor tissues [10^12]. However, recent results of our
group demonstrate that stimulation of cell prolifera-
tion in multicellular spheroids by elevation of the
intracellular redox state resulted in a signi¢cant
downregulation of both P27Kip1 and P-gp [3,13],
pointing towards the notion that P-gp expression
may be indeed related to speci¢c phases of the cell
cycle. The purpose of the present study was to inves-
tigate whether the observed P-gp-mediated intrinsic
resistance is correlated with cell cycle arrest. Several
speci¢c cell cycle inhibitors were administered and
P-gp expression as well as the expression of the
CDK inhibitors P27Kip1 and P21WAFÿ1 were eval-
uated. Our results show that P-gp is upregulated dur-
ing G0/G1 but not during G2/M arrest and is closely
associated to the expression of p27Kip1 which may be
used as tumor marker for intrinsic P-gp-mediated
drug resistance.
2. Materials and methods
2.1. Culture technique of multicellular spheroids
The human prostate cancer cell line DU-145 was
kindly provided by Dr. J. Carlsson, Uppsala, Swe-
den. The cells were grown routinely in 5% CO2/hu-
midi¢ed air at 37‡C with Ham’s F10 medium (Gibco
Life Technologies, Helgerman Court, MD, USA)
supplemented with 10% (v/v) fetal calf serum (Boehr-
inger, Mannheim, Germany), 2 mM glutamine, 0.1
mM L-mercaptoethanol, 2 mM MEM, 100 IU/ml
penicillin and 100 Wg/ml streptomycin (ICN Flow,
Meckenheim, Germany). Spheroids were grown
from single cells. Cell monolayers were enzymatically
dissociated with 0.2% (w/v) trypsin, 0.05% (w/v)
EDTA (ICN Flow) and seeded in siliconized 250
ml spinner £asks (Tecnomara, Fernwald, Germany)
with 250 ml complete medium and agitated at 20
rpm using a Cellspin stirrer system (Integra Bioscien-
ces, Fernwald, Germany). Cell culture medium was
partially (100 ml) changed every day.
2.2. Incubation with cell cycle inhibitors
For incubation with cell cycle inhibitors small mul-
ticellular tumor spheroids (diameter 100 þ 50 Wm,
day 5) were transferred to bacteriological tissue cul-
ture dishes (diameter 10 cm) (Becton Dickinson,
Meylan, France) ¢lled with 10 ml F10 cell culture
medium. They were subsequently treated either for
24 h with 500 WM mimosine, for 3 h with 30 WM
mitomycin C (Sigma, Deisenhofen, Germany), for 24
h with 100 WM roscovitine (Sigma), for 24 h with 20
nM staurosporine (Sigma), or they were cultivated
for 24 h under serum starvation. For induction of
apoptosis glioma spheroids of the cell line Gli36
were incubated for 3 h with 1 WM staurosporine.
For determination of growth curves the compounds
were applied for 4 days.
2.3. Confocal laser scanning microscopy
Fluorescence recordings were performed by means
of a confocal laser scanning setup (LSM 410, Carl
Zeiss, Jena, Germany) equipped with an 488 nm ar-
gon ion laser and two helium-neon lasers with lines
of 543 nm and 633 nm. The confocal setup was con-
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nected to an inverted microscope (Axiovert 135, Carl
Zeiss). Fluorophores were excited using a 0.5 mW
helium-neon laser (single excitation at 543 nm). A
25U, N.A. 0.8, oil immersion-corrected objective
(Carl Zeiss) was applied. Fluorescence was measured
in 3600 Wm2 areas in a depth of 60 Wm from the
spheroid periphery. The thickness of the optical sec-
tions amounted to 20 Wm.
2.4. Immunohistochemical techniques and quantitative
immunohistochemistry
Antibody staining was performed on whole mount
multicellular spheroids as well as on single cells en-
zymatically dissociated from tumor spheroids. The
monoclonal antibody (mAb) anti-p27Kip1 was ob-
tained from Pharmingen (Hamburg, Germany) and
was used at a concentration of 2.5 Wg/ml in phos-
phate-bu¡ered saline supplemented with 0.01% Tri-
ton X-100 (Sigma) (PBST) and containing 10% (w/v)
fat-free milk powder. The mAb anti-p21WAFÿ1 was
obtained from Pharmingen and was used at a con-
centration of 5 Wg/ml in Tris-bu¡ered saline (TBS)
containing 3% (v/v) FCS. The polyclonal anti-mdr
(Ab-1) antibody (Oncogene Research Products,
Cambridge, UK) was used at a concentration of
5 Wg/ml in 0.01% PBST. The polyclonal anti-cas-
pase-3 (D-175) antibody (Cell Signaling Technology,
Beverly, MA, USA) was used at a dilution of 1/100
in TBS supplemented with 0.1% Triton X-100
(TBST) and containing 5% (v/v) FCS. Spheroids
were washed in phosphate-bu¡ered saline (PBS)
and were either ¢xed in ice-cold methanol/acetone
(7:3) for 1 h (anti-p27Kip1) or in 4% paraformalde-
hyde in PBS at 4‡C for 1 h (anti-p21WAFÿ1, anti-
caspase-3, anti-mdr). Subsequently they were per-
meabilized with 1% PBST. Prior to immunostaining
spheroids were incubated for 1 h in 0.01% PBST
containing 10% fat-free milk powder to reduce non-
speci¢c binding. The primary antibody was applied
overnight at 4‡C (anti-p21WAFÿ1, anti-caspase-3) or
for 2 h at room temperature (anti-p27Kip1, anti-mdr).
After washing three times in 0.01% PBST or 0.1%
TBST (anti-p21WAFÿ1, anti-caspase-3) spheroids were
incubated for 60 min in 0.01% PBST supplemented
with 10% milk powder and either a Cy5-conjugated
F(abP)2 fragment goat anti-mouse IgG (H+L)
(Boehringer-Mannheim) (concentration 3.25 Wg/ml)
or a Cy5-conjugated F(abP)2 fragment goat anti-rab-
bit IgG (H+L) (Boehringer-Mannheim) (concentra-
tion 4.6 Wg/ml). In double labeling experiments with
single cells P-gp was labeled by a Cy5-conjugated
F(abP)2 fragment goat anti-rabbit IgG (H+L), where-
as p27Kip1 was labeled by a Cy3-conjugated F(abP)2
fragment goat anti-mouse IgG (H+L) antibody. Ex-
citation was performed using either a 633 nm or a
543 nm helium-neon laser of the confocal setup.
Emission was recorded using either a long pass
(LP) LP655 nm or a LP570 nm ¢lter set.
For quantitative immunohistochemistry confocal
images of whole mount multicellular spheroids
stained with only secondary antibodies (background
£uorescence image) and spheroids stained with pri-
mary and secondary antibodies were recorded. The
pinhole settings of the confocal setup were adjusted
to yield optical slices of 20 Wm thickness. After sub-
traction of background £uorescence the £uorescence
signal (counts) was evaluated by the image analysis
software of the confocal setup in 3600 Wm2 areas of
interest and routinely exported for further analysis to
the Sigma Plot graphic software.
2.5. Evaluation of tumor spheroid growth
Tumor spheroids were treated with cell cycle in-
hibitors for 4 days. The small and large diameters of
untreated spheroids or spheroids treated with agents
as described above were determined. Spheroid vol-
umes were calculated according to V = 4/3WZWaWb2,
where a represents the large half axis and b the small
half axis of the respective tumor spheroid. The
growth of tumor spheroids was evaluated every 24 h.
2.6. Determination of cell cycle
The DNA content of cells from each preparation
was determined by £ow cytometry (Calibur Cytom-
eter, Becton Dickinson, Heidelberg, Germany) anal-
ysis after staining the nuclei with propidium iodide.
Prior to staining multicellular spheroids were disso-
ciated to gain a single cell suspension using trypsin/
EDTA for 5 min at 37‡C. Following centrifugation
the cell pellet was washed three times with citrate
bu¡er (0.25 M sucrose, 0.04 M sodium citrate, 5%
v/v DMSO, pH 7.6, 4‡C). The cells were stained us-
ing the Cycle TEST PLUS DNA Reagent Kit (Bec-
BBAMCR 14834 21-2-02 Cyaan Magenta Geel Zwart
M. Wartenberg et al. / Biochimica et Biophysica Acta 1589 (2002) 49^62 51
ton Dickinson) according to the supplier’s manual.
In principle, cell membrane lipids were dissolved with
a non-ionic detergent, cell cytoskeleton and nuclear
proteins were eliminated with trypsin and cellular
RNA was digested with RNase prior to staining
with propidium iodide. The preparations were kept
on ice in the dark until £ow cytometry analysis was
performed. Propidium iodide £uorescence was ex-
cited with an argon ion laser (488 nm) and the emit-
ted £uorescence light between 564 and 606 nm was
analyzed using a 585/42 band pass ¢lter. To analyze
the data the Cell Quest Programm (Becton Dickin-
son) was used.
2.7. Determination of cell lethality with SYTOX
After 24 h of incubation with cell cycle inhibitors
the medium was exchanged for fresh F10 medium
supplemented with 1 WM SYTOX green (Molecular
Probes, Eugene, OR, USA) which intensively stains
the nuclei of cells with compromised cell membranes.
Following 1 h of incubation the percentage of la-
beled lethal cells was assessed using the 488 nm
band of the argon laser of the confocal setup and a
long pass LP515 nm ¢lter set.
2.8. Determination of intracellular reactive oxygen
species (ROS) levels
Intracellular ROS levels were measured using the
£uorescent dye 2P,7P-dichlorodihydro£uorescein di-
acetate (H2DCFDA) (Molecular Probes), which is a
non-polar compound that is converted into a non-
£uorescent polar derivative (H2DCF) by cellular es-
terases after incorporation into cells. H2DCF is
membrane impermeable and is rapidly oxidized to
the highly £uorescent 2P,7P-dichloro£uorescein
(DCF) in the presence of intracellular ROS [14].
For the experiments, multicellular tumor spheroids
were incubated in E1 medium containing (in mM)
NaCl 135, KCl 5.4, CaCl2 1.8, MgCl2 1, glucose
C
Fig. 1. Representative £ow cytometry plots with cells dissoci-
ated from tumor spheroids at di¡erent times of multicellular
spheroid culture (A, 1-day-old; B, 9-day-old; C, 19-day-old; D,
33-day-old). The data are presented as histograms of cellular
DNA content in order to facilitate computer-assisted interpreta-
tion.
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10, HEPES 10 (pH 7.4 at 23‡C) and 20 WM
H2DCFDA dissolved in dimethyl sulfoxide
(DMSO) was added. After 5, 10, 15, 20, and 30
min intracellular DCF £uorescence (corrected for
background £uorescence) was evaluated in 3600
Wm2 regions of interest using an overlay mask. For
£uorescence excitation, the 488 nm band of the ar-
gon ion laser of the confocal setup was used. Emis-
sion was recorded using a long pass LP515 nm ¢lter
set.
2.9. Statistical analysis
Data are given as mean values þ S.D., with n de-
noting the number of experiments. In each experi-
ment, at least 20 multicellular spheroids were ana-
lyzed. Student’s t-test for unpaired data was
applied as appropriate. A value of P6 0.05 was con-
sidered signi¢cant.
3. Results
3.1. Distribution of speci¢c cell cycle phases in
multicellular tumor spheroids
Multicellular spheroids of di¡erent size classes and
age were enzymatically dissociated and the distribu-
tion of cell cycle phases was investigated by £ow cy-
tometry analysis (Figs. 1A^D and 2A^C) (n = 3). The
number of cells in the G0/G1 phase of the cell cycle
increased from 49 þ 0.2% to 73 þ 2% in 1^3-day-old
and 20^30-day-old multicellular spheroids, respec-
tively. The number of cells in the S phase of the
cell cycle was maximum in 1^3-day-old multicellular
spheroids with 24 þ 1% and declined with increasing
age of the spheroid culture to a minimum of 13 þ 2%
in multicellular spheroids between days 15 and 19. In
parallel, the number of cells in the G2/M phase de-
clined from 27 þ 1% in 1^3-day-old multicellular
spheroids to a minimum of 13 þ 2% in 20^30-day-
old multicellular spheroids.
3.2. Correlation of p27Kip1 and P-gp expression in
DU-145 tumor spheroids
We have previously evidenced in whole mount
multicellular tumor spheroids that with increasing
size and age of the spheroid culture the cell quies-
cence-associated CDK inhibitors p27Kip1 and
p21WAFÿ1 were upregulated whereas the proliferative
antigen Ki-67 was downregulated [13]. Furthermore,
the increase in the fraction of G0/G1 phase cells
during the time course of tumor spheroid culture
was paralleled by an increase in P-gp expression
(Fig. 3A). To demonstrate the correlation of
p27Kip1 and P-gp on the single cell level, small
(1^3-day-old) as well as large (15^19-day-old) tumor
spheroids were enzymatically dissociated and the
expression levels of p27Kip1 and P-gp were evaluated
by double-label immunohistochemistry and confocal
laser scanning microscopy. As shown in Fig. 3C a
signi¢cant proportion of cells dissociated from large
tumor spheroids displayed elevated levels of p27Kip1
Fig. 2. Distribution of the cells in cell cycle phases G0/G1 (A),
S (B) and G2/M (C) at di¡erent times of the culture of multi-
cellular spheroids as evaluated by the use of £ow cytometry ex-
periments. Small spheroids are highly proliferative; with on-
going culture time and tumor spheroid size the percentage of
non-proliferating cells increases.
BBAMCR 14834 21-2-02 Cyaan Magenta Geel Zwart
M. Wartenberg et al. / Biochimica et Biophysica Acta 1589 (2002) 49^62 53
as well as P-gp expression, indicating that these cells
may be arrested in the G0/G1 phase of the cell cycle
(n = 3). By contrast, in cells derived from exponen-
tially growing small tumor spheroids expression of
p27Kip1 as well as P-gp was marginal (see Fig. 3B)
(n = 3), which supports the notion of the present
study that P-gp expression may be correlated with
cell cycle arrest.
3.3. Cell cycle phases upon treatment of tumor
spheroids with cell cycle inhibitors
To investigate the possible correlation of speci¢c
cell quiescence-associated cell cycle phases and P-gp
expression in more detail, various cell cycle inhibitors
which cause cell cycle arrest at speci¢c phases were
applied to multicellular spheroids at an age (5-day-
Fig. 3. Correlation of p27Kip1 and P-gp expression in multicellular DU-145 tumor spheroids. (A) Intrinsic expression of P-gp in whole
mount small 4-day-old (left) and large 12-day-old (right) multicellular tumor spheroids. Shown are representative whole mount tumor
spheroids immunostained with an antibody (Ab-1) directed against P-gp. The settings of the confocal microscope were chosen to rec-
ord optical sections of 10 Wm thickness in a depth of 40 Wm within the spheroid tissue. False colors. The bar represents 50 Wm. (B,C)
Correlation of p27Kip1 and P-gp expression in single cells enzymatically dissociated from small (3-day-old) (B) and large (19-day-old)
tumor spheroids (C). Enzymatically dissociated single cells were double-labeled by antibodies directed against p27Kip1 and P-gp and
protein expression was evaluated by confocal laser scanning microscopy. Shown is one representative of three experiments which
yielded comparable results.
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old) just prior to the induction of cell quiescence in
the depth of the tumor tissue. Multicellular spheroids
at day 5 of spheroid culture (diameter 100 þ 50 Wm)
expressing marginal levels of P-gp [3,9] were treated
with either mimosine (500 WM), mitomycin C (30
WM), roscovitine (100 WM), staurosporine (20 nM)
or serum-free conditions for 4 days. Under serum-
free conditions and upon treatment with staurospo-
rine cells are known to be arrested in the G0/G1
phase of the cell cycle [15]; mimosine has been pre-
viously reported to induce G0/G1 arrest by enhancing
the levels of p27Kip1 [16]; mitomycin has been re-
cently evidenced to inhibit S phase progression [17],
and roscovitine inhibits the cyclin-dependent kinases
CDK2 as well as cdc2 and arrests the cell cycle in the
G2/M phase [18]. Every 24 h mean diameters of sphe-
roids were recorded and the relative volume increase
was calculated. As shown in Fig. 4A, the growth
kinetics were signi¢cantly reduced in all treated sam-
ples as compared to the untreated controls (n = 3). In
parallel experiments cell lethality was assessed using
the lethal cell stain SYTOX green (1 WM). No cell
lethality occurred upon treatment with cell cycle in-
hibitors (data not shown). Moreover, immunohisto-
chemistry with anti-caspase-3 revealed that within 24
h no induction of apoptosis occurred (Fig. 4B)
(n = 3). As a positive control for anti-caspase-3, mul-
ticellular tumor spheroids of the glioma cell line
Gli36 staining were incubated with 1 WM staurospo-
rine for 3 h which resulted in pronounced apoptosis
with approx. 200% increase in immuno£uorescence
(Fig. 4B, insert).
To obtain further information on the speci¢c
phases in the cell cycle where cell cycle arrest oc-
curred upon treatment with cell cycle inhibitors, a
£ow cytometry analysis was performed (Fig. 5).
Small tumor spheroids (5-day-old) were transferred
to bacteriological Petri dishes and incubated for 24 h
with either mimosine, roscovitine, staurosporine, se-
rum-free medium, or for 3 h with mitomycin C. After
propidium iodide staining of cellular DNA and £ow
cytometry analysis the cell cycle distribution in the
control sample of multicellular spheroids in liquid
overlay culture was determined to 65 þ 3% cells in
G0/G1 phase, 15 þ 2% cells in S phase and 20 þ 1%
cells in G2/M phase (n = 4). Treatment with either
mimosine, serum-free conditions or staurosporine in-
creased the percentage of cells in the G0/G1 cell cycle
phase to 75 þ 5%, 78 þ 3% and 79 þ 2%, respectively
(n = 3). Treatment of tumor spheroids with roscovi-
tine as well as mitomycin C increased the number of
cells in the S phase of the cell cycle to 27 þ 5% and
Fig. 4. Growth kinetics (A) and apoptosis (B) in multicellular
DU-145 spheroids following treatment with mimosine, mitomy-
cin C, roscovitine, serum-free medium and staurosporine. Note
that all applied cell cycle inhibitors signi¢cantly depressed tu-
mor spheroid growth as compared to the untreated control. No
signs of apoptosis induction as evaluated by anti-caspase-3 im-
munohistochemistry were observed in prostate tumor spheroids
which were treated with cell cycle inhibitors. As positive control
Gli36 glioma spheroids were treated with 1 WM staurosporine
for 3 h to induce apoptosis (insert). *P6 0.05, signi¢cantly dif-
ferent from the untreated control.
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22 þ 7%, respectively. Arrest in the G2/M phase of
the cell cycle with 30.5 þ 8% of total cells (n = 4)
was achieved upon treatment of tumor spheroids
with roscovitine.
3.4. Expression of the CDK inhibitors p27Kip1 and
p21WAFÿ1 following treatment of tumor spheroids
with cell cycle antagonists
Cell cycle arrest induced by pharmacological
agents may alter the expression of p27Kip1 and
p21WAFÿ1, thereby abrogating progression through
the cell cycle. To investigate this issue 5-day-old tu-
mor spheroids were incubated for 24 h with cell cycle
inhibitors and the expression of p27Kip1 (Fig. 6A,B)
and p21WAFÿ1 (Fig. 7A,B) was investigated by quan-
titative immunohistochemistry. Treatment of tumor
spheroids with either mimosine or incubation in se-
rum-free cell culture medium signi¢cantly increased
the level of p27Kip1 to 127 þ 5% and 166 þ 7%, respec-
tively (n = 3), whereas upon treatment with stauro-
sporine p27Kip1 levels remained unchanged (un-
treated control set to 100%). The expression of
p27Kip1 was signi¢cantly decreased to 78 þ 3% and
89 þ 4% in the roscovitine- and mitomycin C-treated
samples, respectively (n = 3). In contrast, the level of
p21WAFÿ1 remained unchanged in the mimosine-
treated sample and was signi¢cantly increased to
131 þ 7% and 123 þ 4% upon incubation of tumor
spheroids in serum-free cell culture medium and
staurosporine, respectively (n = 3). Roscovitine and
mitomycin C treatment resulted in a signi¢cant
downregulation of p21WAFÿ1 to 87 þ 3% and to
82 þ 3%, respectively (n = 3).
3.5. Expression of P-gp following treatment of
multicellular tumor spheroids with cell cycle
inhibitors
To correlate the cell cycle arrest at di¡erent states
of the cell cycle with the level of P-gp, changes of P-
gp expression were investigated after treatment with
either mimosine, mitomycin C, roscovitine, or incu-
bation in serum-free cell culture medium (Fig. 8). In
parallel to the observed elevation in the expression of
p27Kip1 (see Fig. 6) the expression of P-gp was sig-
ni¢cantly increased to 136 þ 8% in the mimosine-
treated sample and to 144 þ 13% in the serum-free
Fig. 5. Flow cytometry analysis of cell cycle distribution after propidium iodide staining. The cell cycle phases of tumor cells were in-
vestigated after treatment with the cell cycle inhibitors mimosine, mitomycin C, roscovitine, staurosporine as well as following incuba-
tion in serum-free medium. Shown is a representative analysis of the cell cycle distribution of cells in (A) the G0/G1 phase, (B) the
S phase, and (C) the G2/M phase of the cell cycle. *P6 0.05, signi¢cantly di¡erent from the untreated control.
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treated sample, whereas staurosporine, which compa-
rably to mimosine and serum-free conditions arrested
cells in the G0/G1 phase, signi¢cantly downregulated
P-gp expression to 64 þ 14% of the control (n = 4)
(untreated control set to 100%). Upon treatment
with mitomycin C and roscovitine the P-gp level re-
mained unchanged (n = 4).
3.6. Elevation of intracellular ROS and redox-
sensitive regulation of P-gp by staurosporine
The data of the present study demonstrate that
staurosporine downregulated P-gp expression
although this agent is known to induce G0/G1 arrest.
By contrast our data with mimosine and serum-free
Fig. 6. Expression of p27Kip1 following treatment of small spheroids with cell cycle inhibitors. (A) Representative tumor spheroids
treated (from the left to the right) with mimosine, mitomycin C, roscovitine, serum-free conditions and staurosporine. The £uorescence
was assessed with confocal microscopy in optical sections at a depth between 20 and 60 Wm in the tumor tissue. The bar represents
50 Wm. (B) Quantitative analysis of p27Kip1 immuno£uorescence in multicellular tumor spheroids treated with cell cycle inhibitors.
Note that p27Kip1 expression was increased in the samples treated with mimosine and serum-free medium. *P6 0.05, signi¢cantly dif-
ferent from the untreated control.
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medium show that G0/G1 arrest induced by these
compounds resulted in an upregulation of P-gp. Pre-
vious studies of our group suggested that P-gp ex-
pression is regulated by ROS [3,13]. Furthermore,
staurosporine has been recently shown to elevate
the intracellular ROS levels [19]. To investigate
whether the downregulation of P-gp by staurospo-
rine was owing to an elevation of ROS, the intra-
cellular redox state was evaluated by the use of the
redox-sensitive dye H2DCFDA. As shown in Fig. 9A
staurosporine signi¢cantly increased the oxidation ki-
netics of H2DCF to £uorescent DCF, indicating an
increased rate of ROS generation (n = 3). By contrast
neither roscovitine, mitomycin C and mimosine
Fig. 7. Expression of p21WAFÿ1 following treatment of small spheroids with cell cycle inhibitors. (A) Representative tumor spheroids
treated (from the left to the right) with mimosine, mitomycin C, roscovitine, serum-free conditions and staurosporine. (B) Quantitative
analysis of p27WAFÿ1 immuno£uorescence in multicellular tumor spheroids treated with cell cycle inhibitors. The £uorescence was as-
sessed with confocal microscopy in optical sections at a depth between 20 and 60 Wm in the tumor tissue. The bar represents 50 Wm.
Note that p21WAFÿ1 expression was signi¢cantly increased in the samples treated with serum-free conditions and staurosporine.
*P6 0.05, signi¢cantly di¡erent from the untreated control.
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treatment nor incubation in serum-free medium sig-
ni¢cantly altered intracellular ROS levels (data not
shown).
If the downregulation of P-gp was caused by an
elevation of intracellular ROS, an inhibition of
ROS generation by coadministration of free radical
scavengers should abrogate the observed e¡ect. To
evaluate this point multicellular tumor spheroids
were preincubated with the free radical scavenger
ebselen (1 WM) prior to the addition of stauro-
sporine. This treatment completely abolished the
downregulation of P-gp following incubation with
staurosporine (Fig. 9B) (n = 3), indicating that the
e¡ect of staurosporine on P-gp expression was medi-
Fig. 8. Expression of P-gp following treatment of small tumor spheroids with the cell cycle inhibitors mimosine, mitomycin C, roscovi-
tine, serum-free medium and staurosporine. (A) Representative tumor spheroids treated (from the left to the right) with mimosine, mi-
tomycin C, roscovitine, serum-free conditions and staurosporine. The £uorescence was assessed with confocal microscopy in optical
sections at a depth between 20 and 60 Wm in the tumor tissue. The bar represents 50 Wm. (B) Quantitative analysis of P-gp immuno-
£uorescence in multicellular tumor spheroids treated with cell cycle inhibitors. Note that the P-gp expression was signi¢cantly in-
creased in the samples treated with mimosine and serum-free medium. Staurosporine downregulated P-gp expression. *P6 0.05, signif-
icantly di¡erent from the untreated control.
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ated by its property to elevate intracellular ROS
levels.
4. Discussion
Intensive e¡orts have been undertaken in recent
years to discover new drugs targeting the cell cycle
as potential therapeutics of cancer [20,21]. In general,
highly proliferative cells are more sensitive towards
chemotherapy. This has been achieved by the devel-
opment of anticancer drugs which interfere with cell
cycle progression on di¡erent levels, e.g. through in-
hibition of mitogen activated protein kinase path-
ways [22], inhibition of cyclin-dependent protein ki-
nases [23], accumulation in the G2/M phase of the
cell cycle owing to the induction of DNA strand
breaks [24], as well as intercalation into the DNA
during the S phase of the cell cycle [25]. However,
with increasing size most solid tumors in vivo devel-
op a proliferative heterogeneity in tumor regions
with limited angiogenesis as a result of hypoxia and
insu⁄cient nutrient supply. Commonly, the prolifer-
ative heterogeneity is accompanied by an increased
resistance to chemotherapeutic drugs in subpopula-
tions of the tumor and an upregulation of CDK in-
hibitors which interfere with the progression of the
cell cycle [26].
The CDK inhibitor P27Kip1, which is predomi-
nantly expressed in cells with tight intercellular con-
tact, has been proposed as a resistance factor since
upregulation of p27Kip1 coincided with the occur-
rence of drug resistance [6]. This assumption was
validated by the use of antisense oligonucleotides to
downregulate P27Kip1 which resulted in loss of aggre-
gation and a signi¢cant increase in the sensitivity to
alkylating agents [6]. In line with these ¢ndings pre-
vious studies of our group suggested a correlation
between elevated P27Kip1 expression and the appear-
ance of a MDR phenotype, since MDR was predom-
inantly detected in quiescent cell areas which dis-
played a parallel expression of p27Kip1 and P-gp
[3,9,13]. Therefore, it had to be investigated whether
the cell quiescence-related increase in P-gp expression
was generally owing to a decrease in the proliferation
rate of tumor cells in the depth of the three-dimen-
sional tumor tissue, or whether cell cycle arrest in a
speci¢c phase of the cell cycle was a prerequisite for
P-gp induction.
To address these issues several known cell cycle
inhibitors which arrest the cell cycle at speci¢c phases
were applied to exponentially growing tumor sphe-
roids, and subsequently the expression levels of P-gp
as well as of the CDK inhibitors p27Kip1 and
p21WAFÿ1 were investigated. Using the plant amino
acid mimosine, it was shown that a signi¢cant stim-
ulation of p27Kip1 expression as well as an increase in
Fig. 9. Elevation of intracellular ROS by staurosporine (A) and
ROS-mediated downregulation of P-gp (B). Endogenous genera-
tion of ROS was investigated using the redox-sensitive dye
H2DCFDA. The DCF £uorescence increase was recorded for
30 min. The £uorescence value at 30 min in every control mea-
surement was set to 100% and was set in relation to the stauro-
sporine-treated sample. The downregulation of P-gp expression
in B following treatment for 24 h with staurosporine was abol-
ished after coadministration of the free radical scavenger ebse-
len, indicating that the observed e¡ect was owing to the en-
hancement of ROS generation by this compound. *P6 0.05,
signi¢cantly di¡erent from the untreated control.
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P-gp levels occurred, whereas the expression level of
p21WAFÿ1 remained unchanged. This is in line with
the observation of a recent study demonstrating that
mimosine arrests cells at the G1/S border by enhanc-
ing the levels of p27Kip1 [16]. Serum starvation, which
causes a general arrest of cells in the G0/G1 phase
[27], elevated the levels of both p27Kip1 and
p21WAFÿ1 and increased the expression level of
P-gp. In a reporter gene assay it has been previously
demonstrated that serum starvation directly acti-
vated the MDR-1 promoter [2]. In the present study
mitomycin C, which inhibits S phase progression in
Rb (+/+) mouse embryo ¢broblasts [17], signi¢cantly
decreased the expression of p27Kip1 as well as
p21WAFÿ1, whereas P-gp levels remained unchanged.
This is in contrast to a recent study which demon-
strated a downregulation of MDR-1 mRNA as well
as P-gp levels following treatment of xenografted
P-gp overexpressing cells with non-cytotoxic doses
of mitomycin C [28]. Roscovitine, a potent and se-
lective inhibitor of cyclin-dependent kinases cdc2 and
Cdk2, induces changes in cell cycle distribution. Us-
ing £ow cytometry analysis a recent study evidenced
a decrease in the number of S phase cells in parallel
to an increase in the number of G2/M phase cells
[18]. Comparable results, i.e. an increase in the num-
ber of cells in the S phase as well as in the G2/M
phase, were achieved in the present study. Further-
more, it was observed that roscovitine treatment de-
creased p27Kip1 and p21WAFÿ1 levels, whereas the
P-gp expression remained unchanged. Apparently
pharmacological inhibition of Cdk2 resulted in
downregulation of endogenous physiological Cdk2
inhibitors, i.e. p27Kip1 and p21WAFÿ1. Our data con-
clusively evidence that upregulation of p27Kip1 in
multicellular spheroids is paralleled by an increased
P-gp expression, corroborating the function of
p27Kip1 as a resistance factor [6]. However, downreg-
ulation of p27Kip1 did not inevitably result in a loss
of P-gp expression, since downregulation of p27Kip1
by roscovitine as well as mitomycin C treatment did
not a¡ect P-gp expression. The data of the present
study indicate that cell cycle arrest is not generally
regulating P-gp since cell cycle arrest in the G2/M
and in the S phase of the cell cycle did not a¡ect
P-gp expression. Furthermore, staurosporine treat-
ment downregulated P-gp although it arrested the
G0/G1 phase of the cell cycle comparably to mimo-
sine and serum-free cell culture medium. The down-
regulation of P-gp by staurosporine was apparently
owing to the previously reported generation of ROS
via the mitochondrial respiratory chain [19]. Inhibi-
tion of P-gp function following treatment of drug-
resistant cells with staurosporine has previously
been reported but was attributed to the inhibition
of protein kinase C (PKC) activity which is required
for the phosphorylation and activation of P-gp
[29^31]. There is also evidence for a circumvention
of P-gp-mediated MDR by staurosporine independ-
ent of PKC activity [32,33], which may be related to
downregulation of MDR-1 mRNA and P-gp expres-
sion [34].
Previous studies of our group suggest that P-gp
expression in multicellular prostate tumor spheroids
is regulated by the intracellular redox state which is
maintained by the balance between ROS generation
and the activity of the antioxidant defense system
[3,13]. Low concentrations of ROS which induced
cell proliferation downregulated P-gp as well as
p27Kip1 expression. Hence it sounds reasonable that
under stress conditions which are present in hypoxic,
avascular microregions of tumors p27Kip1 contributes
to a cell cycle arrest that is essential for cell survival,
whereas P-gp contributes to cell survival by its prop-
erty to detoxify the tissue from catabolic waste prod-
ucts. Thus, possible roles of p27Kip1 and P-gp may be
to coordinate cell cycle, cell death and detoxi¢cation
programs in order to protect cells from external in-
sults which may explain the parallel expression of
both proteins observed in multicellular tumor sphe-
roids.
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